cisplatin,pembrolizumab,vibostolimab,favezelimab
merck
['gu ', 'mibc', 'pembro', 'key,note,052', 'key,note,45', 'scot ', 'key,note,52', 'key,note,57', ' cis ', 'nmibc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bladder']
pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non muscle-invasive bladder cancer (hr nmibc) unresponsive to bacillus calmette gu rin (bcg): results from cohort b of the phase 2 keynote-057 trial. #gu23 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid